HK1212683A1 - 多个激酶途径抑制剂 - Google Patents

多个激酶途径抑制剂 Download PDF

Info

Publication number
HK1212683A1
HK1212683A1 HK16100505.0A HK16100505A HK1212683A1 HK 1212683 A1 HK1212683 A1 HK 1212683A1 HK 16100505 A HK16100505 A HK 16100505A HK 1212683 A1 HK1212683 A1 HK 1212683A1
Authority
HK
Hong Kong
Prior art keywords
pathway inhibitors
kinase pathway
multiple kinase
kinase
inhibitors
Prior art date
Application number
HK16100505.0A
Other languages
English (en)
Chinese (zh)
Inventor
Qingping Zeng
Mary Faris
Alexis MOLLARD
Steven L. Warner
Gary A. Flynn
Original Assignee
Mannkind Corporation
Tolero Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mannkind Corporation, Tolero Pharmaceuticals, Inc. filed Critical Mannkind Corporation
Publication of HK1212683A1 publication Critical patent/HK1212683A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK16100505.0A 2012-09-26 2013-09-25 多个激酶途径抑制剂 HK1212683A1 (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261706084P 2012-09-26 2012-09-26
US61/706,084 2012-09-26
US201361757331P 2013-01-28 2013-01-28
US61/757,331 2013-01-28
US201361785992P 2013-03-14 2013-03-14
US61/785,992 2013-03-14
PCT/US2013/061548 WO2014052365A1 (en) 2012-09-26 2013-09-25 Multiple kinase pathway inhibitors

Publications (1)

Publication Number Publication Date
HK1212683A1 true HK1212683A1 (zh) 2016-06-17

Family

ID=50388917

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16100505.0A HK1212683A1 (zh) 2012-09-26 2013-09-25 多个激酶途径抑制剂

Country Status (8)

Country Link
US (2) US9493454B2 (cg-RX-API-DMAC7.html)
EP (1) EP2900668A4 (cg-RX-API-DMAC7.html)
JP (1) JP2015532281A (cg-RX-API-DMAC7.html)
CN (1) CN104812756A (cg-RX-API-DMAC7.html)
AU (1) AU2013323736A1 (cg-RX-API-DMAC7.html)
CA (1) CA2886275A1 (cg-RX-API-DMAC7.html)
HK (1) HK1212683A1 (cg-RX-API-DMAC7.html)
WO (1) WO2014052365A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2734205T3 (en) 2011-07-21 2018-06-14 Tolero Pharmaceuticals Inc Heterocyclic Protein Kinase Inhibitors
HK1212683A1 (zh) * 2012-09-26 2016-06-17 Mannkind Corporation 多个激酶途径抑制剂
PT2970205T (pt) 2013-03-14 2019-08-26 Tolero Pharmaceuticals Inc Inibidores da jak2 e da alk2 e métodos para a sua utilização
CN104418853B (zh) * 2013-08-28 2016-09-07 北大方正集团有限公司 取代的萘啶-2-酮化合物、制备方法、用途及药物组合物
CN105622638B (zh) * 2014-10-29 2018-10-02 广州必贝特医药技术有限公司 嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用
WO2016161248A1 (en) * 2015-04-02 2016-10-06 Tolero Pharmaceuticals, Inc. Targeting pim kinases in combination with btk inhibition
HUE045585T2 (hu) 2015-05-18 2020-01-28 Tolero Pharmaceuticals Inc Megnövelt biológiai hozzáférhetõséggel rendelkezõ Alvocidib gyógyszer-elõanyagok
AU2016301315C1 (en) 2015-08-03 2022-07-07 Sumitomo Pharma Oncology, Inc. Combination therapies for treatment of cancer
CN105130986B (zh) * 2015-09-30 2017-07-18 广州科擎新药开发有限公司 嘧啶或吡啶并吡啶酮类化合物及其应用
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
US10676474B2 (en) 2016-12-16 2020-06-09 Cstone Pharmaceuticals 1,6-naphthyridine derivatives as CDK4/6 inhibitor
CN108264511B (zh) * 2017-01-03 2021-04-13 浙江海正药业股份有限公司 杂环类衍生物及其制备方法和其在医药上的用途
WO2018213219A1 (en) * 2017-05-15 2018-11-22 University Of Houston System Pyrido[2,3-d]pyrimidin-7ones and related compounds as inhibitors of protein kinases
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー, インコーポレイテッド Mcl-1阻害剤アルボシジブを用いた、bcl-2阻害剤に対して非感受性である癌の治療レジメン
BR112020020246A8 (pt) 2018-04-05 2022-10-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de cinase axl e uso dos mesmos
MX2020010556A (es) 2018-04-13 2021-03-02 Sumitomo Pharma Oncology Inc Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer.
KR20210038906A (ko) 2018-07-26 2021-04-08 스미토모 다이니폰 파마 온콜로지, 인크. 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
CA3120850A1 (en) * 2018-12-07 2020-06-11 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating castration-resistant and castration- sensitive prostate cancer
HUE072069T2 (hu) 2019-02-12 2025-10-28 Sumitomo Pharma America Inc 2-((1R,4R)-4-((3-(3-(trifluormetil)fenil)imidazo[1,2- b]piridazin-6-il)amino)ciklohexil)propán-2-ol sósavas sójának kristályos formája
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置
CN117430597A (zh) * 2022-07-14 2024-01-23 浙江同源康医药股份有限公司 用作cdk4激酶抑制剂的化合物及其应用
AU2023372386A1 (en) 2022-10-31 2025-05-08 Sumitomo Pharma America, Inc. Pim1 inhibitor for treating myeloproliferative neoplasms

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5945422A (en) 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
AU742999B2 (en) * 1997-08-20 2002-01-17 Warner-Lambert Company Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
US6303652B1 (en) * 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
EP1590341B1 (en) * 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
WO2005034869A2 (en) * 2003-10-08 2005-04-21 Irm Llc Compounds and compositions as protein kinase inhibitors
JP2009537520A (ja) 2006-05-15 2009-10-29 アイアールエム・リミテッド・ライアビリティ・カンパニー Fgf受容体キナーゼ阻害剤のための組成物および方法
US8604031B2 (en) 2006-05-18 2013-12-10 Mannkind Corporation Intracellular kinase inhibitors
HK1212683A1 (zh) * 2012-09-26 2016-06-17 Mannkind Corporation 多个激酶途径抑制剂

Also Published As

Publication number Publication date
CN104812756A (zh) 2015-07-29
US9493454B2 (en) 2016-11-15
US20150266870A1 (en) 2015-09-24
AU2013323736A8 (en) 2015-04-30
US9714247B2 (en) 2017-07-25
EP2900668A1 (en) 2015-08-05
CA2886275A1 (en) 2014-04-03
EP2900668A4 (en) 2016-04-20
US20170107215A1 (en) 2017-04-20
WO2014052365A1 (en) 2014-04-03
JP2015532281A (ja) 2015-11-09
AU2013323736A1 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
AU2013323736A8 (en) Multiple kinase pathway inhibitors
IL277951A (en) Pyrimidinyls are tyrosine kinase inhibitors
ZA201906377B (en) Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
HK1202377A1 (en) Modulating certain tyrosine kinases
ZA201405140B (en) Disubstituted benzothienyl-pyrolotriazines and their use as fgfr kinase inhibitors
WO2016123054A3 (en) Kinase drug combinations and methods of use thereof
EP3060173A4 (en) Methods and systems for heart valve therapy
WO2012158843A3 (en) Kinase inhibitors
EP3035800A4 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
LT2857404T (lt) Imidazo[1,2-b]piridazino dariniai, kaip kinazės inhibitoriai
EP2683243A4 (en) PI3 KINASE INHIBITORS AND USES THEREOF
EP3113776A4 (en) Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
EP2833889A4 (en) PROTEIN KINASE C HEMMER AND USES THEREOF
ZA201409256B (en) 1,2,4-triazine-6-carboxamide kinase inhibitors
IL235418B (en) Biologically active projectiles, systems, and methods
CL2015001147A1 (es) Terapia adyuvante con inhibidores de quinasa de la familia tec
ZA201406777B (en) 3,5-diaminopyrazole kinase inhibitors
EP2749777A4 (en) HYDRAULIC CIRCUIT, AND COMBINED VALVE USED IN THIS HYDRAULIC CIRCUIT
IL239904A0 (en) Inhibitory oligonucleotides and their use in therapy
EP3068389A4 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
EP2855484A4 (en) PROTEIN KINASE INHIBITORS
EP2968995A4 (en) INHIBITORS OF LRRK2 KINASE ACTIVITY
EP3068378A4 (en) Random copolymer therapeutic agent carriers and assemblies thereof
EP2900243A4 (en) BICYCLIC OXA LACTAM KINASE HEMMER
CA142766S (en) Shelving unit